A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV

Vaccine

Volumn 29, Issue 4, 2011, Pages 744-753

  Somogyi, Eszter ^a   Xu, Jianqing ^c,f   Gudics, Ágnes ^a   Tóth, József ^a   Kovács, Attila L ^d   Lori, Franco ^e   Lisziewicz, Julianna ^a,b  

^a Genetic Immunity   (Hungary)

^b Genetic Immunity   (United States)

^c Research Institute for Genetic and Human Therapy   (United States)

^d EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^e ViroStatics Srl   (Italy)

^f FUDAN UNIVERSITY   (China)

Author keywords

DermaVir; HIV immunotherapy; Therapeutic vaccine

Indexed keywords

EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; PLASMID DNA;

ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DNA INTEGRATION; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION; VIRUS LIKE AGENT; VIRUS REPLICATION;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; EPITOPES, T-LYMPHOCYTE; HIV ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; PLASMIDS; SEQUENCE ANALYSIS, DNA; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINES, VIROSOME;

EID: 78650541311     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.019     Document Type: Article

References (56)

1. Pantaleo G., Demarest J.F., Schacker T., Vaccarezza M., Cohen O.J., Daucher M., et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(1):254-258.
2. Wyand M.S., Manson K., Montefiori D.C., Lifson J.D., Johnson R.P., Desrosiers R.C. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. Journal of Virology 1999, 73(10):8356-8363.
3. Gundlach B.R., Lewis M.G., Sopper S., Schnell T., Sodroski J., Stahl-Hennig C., et al. Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. Journal of Virology 2000, 74(8):3537-3542.
4. Paovonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
5. Villa L.L., Perez G., Kjaer S.K., Paavonen J., Lehtinen M., Munoz N., et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine 2007, 356(19):1915-1927.
6. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection-a randomized trial. JAMA-Journal of the American Medical Association 2007, 298(7):743-753.
7. Broliden K., Hinkula J., Devito C., Kiama P., Kimani J., Trabbatoni D., et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunology Letters 2001, 79(1-2):29-36.
8. Rowland-Jones S., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., et al. HIV-specific cytoptoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Medicine 1995, 1(1):59-64.
9. Rosenberg E.S., LaRosa L., Flynn T., Robbins G., Walker B.D. Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Immunology Letters 1999, 66(1-3):89-93.
10. Lisziewicz J., Rosenberg E., Lieberman J., Jessen H., Lopalco L., Siliciano R., et al. Control of HIV despite the discontinuation of antiretroviral therapy. New England Journal of Medicine 1999, 340(21):1683-1684.
11. Johnson R.P., Glickman R.L., Yang J.Q., Kaur A., Dion J.T., Mulligan M.J., et al. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. Journal of Virology 1997, 71(10):7711-7718.
12. Busch M., Abel K., Li J., Piatak M., Lifson J.D., Miller C.J. Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge. Vaccine 2005, 23(31):4036-4047.
13. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372(9653):1894-1905.
14. Toke E.R., Lorincz O., Somogyi E., Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. International Journal of Pharmaceutics 2010, 392(1-2):261-267.
15. Lisziewicz J., Trocio J., Whitman L., Varga G., Xu J.Q., Bakare N., et al. DermaVir: a novel topical vaccine for HIV/AIDS. Journal of Investigative Dermatology 2005, 124(1):160-169.
16. Phase I:; Phase II:, ctgov:NCT00711230.
17. Gudics A., Lisziewicz J. Nanomedicine for dendritic cell-targeted immunotherapy. European Journal of Nanomedicine 2010, 3(1):25-29.
18. Lori F., Veronese F.D., Devico A.L., Lusso P., Reitz M.S., Gallo R.C. Viral-DNA carried by human-immunodeficiency-virus type-1 virions. Journal of Virology 1992, 66(8):5067-5074.
19. Malykh A., Reitz M.S., Louie A., Hall L., Lori F. Multiple determinants for growth of human-immunodeficiency-virus type-1 in monocyte-macrophages. Virology 1995, 206(1):646-650.
20. Piccinini G., Foli A., Comolli G., Lisziewicz J., Lori F. Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes. Journal of Virology 2002, 76(5):2274-2278.
21. http://tools.immuneepitope.org/.
22. Peters B., Bui H.H., Frankild S., Nielsen M., Lundegaard C., Kostem E., et al. A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Computational Biology 2006, 2(6):574-584.
23. Wang P., Sidney J., Dow C., Mothe B., Sette A., Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Computational Biology 2008, 4(4).
24. Nielsen M., Lundegaard C., Worning P., Lauemoller S.L., Lamberth K., Buus S., et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Science 2003, 12(5):1007-1017.
25. HIV Molecular Immunology 2008 2008, Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico. T.M.B. Korber, C. Brander, B.F. Haynes, R. Koup, J.P. Moore, B.D. Walker (Eds.).
26. Jayan G.C., Cordelier P., Patel C., BouHamdan M., Johnson R.P., Lisziewicz J., et al. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional, and pol III promoters. Gene Therapy 2001, 8(13):1033-1042.
27. Lisziewicz J., Rappaport J., Dhar R. Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene-expression. New Biologist 1991, 3(1):82-89.
28. Gruters R.A., van Baalen C.A., Osterhaus A. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 2002, 20(15):2011-2015.
29. Bera S., Pandey K.K., Vora A.C., Grandgenett D.P. Molecular interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integration. Journal of Molecular Biology 2009, 389(1):183-198.
30. Desrosiers R.C. Strategies used by human immunodeficiency virus that allow persistent viral replication. Nature Medicine 1999, 5(7):723-725.
31. Cara A., Guarnaccia F., Reitz M.S., Gallo R.C., Lori F. Self-limiting, cell type-dependent replication of an integrase defective human-immunodeficiency-virus type-1 in human primary macrophages but not T-lymphocytes. Virology 1995, 208(1):242-248.
32. Vicenzi E., Dimitrov D.S., Engelman A., Migone T.S., Purcell D.F.J., Leonard J., et al. An integration-defective U5 deletion mutant of human-immunodeficiency-virus type-1 reverts by eliminating additional long terminal repeat sequences. Journal of Virology 1994, 68(12):7879-7890.
33. Zhou H.B., Rainey G.J., Wong S.K., Coffin J.M. Substrate sequence selection by retroviral integrase. Journal of Virology 2001, 75(3):1359-1370.
34. Murphy J.E., Goff S.P. Construction and analysis of deletion mutations in the U5 region of moloney murine leukemia-virus-effects on RNA packaging and reverse transcription. Journal of Virology 1989, 63(1):319-327.
35. Schwartz O., Marechal V., LeGall S., Lemonnier F., Heard J.M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nature Medicine 1996, 2(3):338-342.
36. Stumptner-Cuvelette P., Morchoisne S., Dugast M., Le Gall S., Raposo G., Schwartz O., et al. HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(21):12144-12149.
37. Collins K.L., Chen B.K., Kalams S.A., Walker B.D., Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998, 391(6665):397-401.
38. Kirchhoff F., Greenough T.C., Brettler D.B., Sullivan J.L., Desrosiers R.C. Brief Report-absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. New England Journal of Medicine 1995, 332(4):228-232.
39. Kestler H.W., Ringler D.J., Mori K., Panicali D.L., Sehgal P.K., Daniel M.D., et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65(4):651-662.
40. Quan F.S., Steinhauer D., Huang C.Z., Ross T.M., Compans R.W., Kang S.M. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008, 26(26):3352-3361.
41. Ellenberger D., Li B., Smith J., Yi H., Folks T., Robinson H., et al. Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms. Virology 2004, 319(1):118-130.
42. Ellenberger D., Wyatt L., Li B., Buge S., Lanier N., Rodriguez I.V., et al. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology 2005, 340(1):21-32.
43. Blauvelt A., Asada H., Saville M.W., KlausKovtun V., Altman D.J., Yarchoan R., et al. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. Journal of Clinical Investigation 1997, 100(8):2043-2053.
44. Sabado R.L., Kavanagh D.G., Kaufmann D.E., Fru K., Babcock E., Rosenberg E., et al. In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4(+) T cells in acute HIV-1 infection. PLoS ONE 2009, 4(1).
45. Le Gall S., Erdtmann L., Benichou S., Berlioz-Torrent C., Liu L.X., Benarous R., et al. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998, 8(4):483-495.
46. Yang O.O., Nguyen P.T., Kalams S.A., Dorfman T., Gottlinger H.G., Stewart S., et al. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. Journal of Virology 2002, 76(4):1626-1631.
47. Sandstrom E., Nilsson C., Hejdeman B., Brave A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant Modified Vaccinia Virus Ankara. Journal of Infectious Diseases 2008, 198(10):1482-1490.
48. Ellenberger D., Wyatt L., Li B., Buge S., Lanier N., Rodriguez I.V., et al. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immxature VLPs. Virology 2005, 340(1):21-32.
49. Masemola A., Mashishi T., Khoury G., Mohube P., Mokgotho P., Vardas E., et al. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. Journal of Virology 2004, 78(7):3233-3243.
50. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nature Medicine 2007, 13:46-53.
51. Vider-Shalit T., Fishbain V., Raffaeli S., Louzoun Y. Phase-dependent immune evasion of herpesviruses. Journal of Virology 2007, 81(17):9536-9545.
52. Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R., et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nature Medicine 2007, 13(1):100-106.
53. Mouquet H., Scheid J.F., Zoller M.J., Krogsgaard M., Ott R.G., Shukair S., et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467(7315):591-595.
54. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., Schoenberger S.P. CD4(+) T cells are required for secondary expansion and memory in CD8(+) T lymphocytes. Nature 2003, 421(6925):852-856.
55. Lisziewicz J., Gabrilovich D.I., Varga G., Xu J.Q., Greenberg P.D., Arya S.K., et al. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. Journal of Virology 2001, 75(16):7621-7628.
56. Hammonds J., Chen X.M., Zhang X.G., Lee F., Spearman P. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 2007, 25(47):8036-8048.